

Surveillance of adverse events following immunisation in Australia, 2022

15 March 2025



Contents

Contents	2
Abbreviations	3
Summary	5
Introduction	6
Methods	7
AEFI data	7
Serious and non-serious AEFI	8
Data analysis	9
Notes on interpretation	9
Results	10
Reporting rates	10
Vaccines	11
Adverse events	11
Serious adverse events	12
Discussion	14
Conclusion	16
References	17
Tables	19
Figures	23
Supplementary Material	30

Abbreviations

13vPCV	13-valent pneumococcal conjugate vaccine
23vPPV	23-valent pneumococcal polysaccharide vaccine
7vPCV	7-valent pneumococcal conjugate vaccine
ABS	Australian Bureau of Statistics
AEFI	adverse event following immunisation
AEMS	Adverse Event Management System
AIR	Australian Immunisation Register
ATAGI	Australian Technical Advisory Group on Immunisation
CI	confidence interval
DAEN	Database of Adverse Event Notifications
DTP	diphtheria-tetanus-pertussis vaccine – formulation unspecified
DTPa	diphtheria-tetanus-pertussis (acellular) vaccine – paediatric formulation
dTpa	diphtheria-tetanus-pertussis (acellular) vaccine – adult formulation
DTPa-Hib	combined diphtheria-tetanus-pertussis (acellular) and <i>Haemophilus influenzae</i> type b vaccine
DTPa-IPV	combined diphtheria-tetanus-pertussis (acellular) and inactivated poliovirus vaccine – paediatric formulation
DTPa-IPV-HepB-Hib	combined diphtheria-tetanus-pertussis (acellular), inactivated poliovirus, hepatitis B and <i>Haemophilus influenzae</i> type b vaccine
dTpa-IPV	combined diphtheria-tetanus-pertussis (acellular) and inactivated poliovirus vaccine – adult formulation
ERP	estimated resident population
H1N1pdm09	pandemic H1N1 influenza 2009 vaccine
HepA	hepatitis A vaccine
HepB	hepatitis B vaccine
Hib	<i>Haemophilus influenzae</i> type b
Hib-MenC	combined <i>Haemophilus influenzae</i> type b and meningococcal C conjugate vaccine
Hib-MenCY	combined <i>Haemophilus influenzae</i> type b and meningococcal C and Y conjugate vaccine
Hib-HepB	combined <i>Haemophilus influenzae</i> type b and hepatitis B vaccine
HPV	human papillomavirus
ICU	intensive care unit
JE	Japanese encephalitis
MedDRA	Medical Dictionary for Regulatory Activities
MenACWY	quadrivalent meningococcal (serogroups A, C, W-135, Y) conjugate vaccine
MenB	meningococcal B vaccine
MenC	meningococcal C conjugate vaccine
MMR	measles-mumps-rubella vaccine
MMRV	measles-mumps-rubella-varicella vaccine
MVA-BN	modified vaccinia Ankara – Bavarian Nordic vaccine
NCIRS	National Centre for Immunisation Research and Surveillance

NIP	National Immunisation Program
PCV	pneumococcal conjugate vaccine – formulation unspecified
PI	product information
PT	preferred term(s)
SMQ	standardised MedDRA query
TGA	Therapeutic Goods Administration
VPD	vaccine preventable disease
WHO	World Health Organization
Zoster (RZV)	recombinant zoster vaccine
Zoster (ZVL)	live-attenuated zoster vaccine

Summary

This report summarises Australia's spontaneous surveillance data for non-COVID-19 vaccine adverse events following immunisation (AEFI) for 2022, reported to the Therapeutic Goods Administration (TGA). National spontaneous (passive) surveillance data for COVID-19 vaccine AEFI reported to the TGA are analysed and discussed in a separate companion publication.

There were 3,642 AEFI reports for non-COVID-19 vaccines administered in 2022, representing an annual AEFI reporting rate of 14.0 per 100,000 population, compared with 13.4 per 100,000 population in 2021. This very small increase in the AEFI reporting rate in 2022 could potentially be related to the combination of several factors: a gradual return to pre-pandemic AEFI reporting patterns, new vaccination programs in response to outbreaks of emergent vaccine preventable diseases (Japanese encephalitis and mpox), and a change in the reporting activities of pharmaceutical sponsors. AEFI reporting rates for individual vaccines in 2022 were similar to 2021.

This report is a deliverable under contract with the Australian Government Department of Health and Aged Care in relation to services for immunisation research and surveillance, and has been prepared by Yuanfei Anny Huang, Nicholas Wood, Lucy Deng, and Kristine Macartney at the National Centre for Immunisation Research and Surveillance (NCIRS), and Claire Larter, Megan Hickie, Megan O'Moore, Belinda Jones, Sophie Russell, and Elspeth Kay at the Therapeutic Goods Administration. We would also like to acknowledge and thank Alexandra Hendry and Tristan Franks at NCIRS for providing historical context and code and vaccine dose data from the Australian Immunisation Register.

Introduction

An adverse event following immunisation (AEFI) is defined as any untoward medical occurrence which follows immunisation and which does not necessarily have a causal relationship with the usage of the vaccine.¹ The AEFI may be an unfavourable or unintended sign, abnormal laboratory finding, symptom or disease. AEFI can be caused by the vaccine(s) or be a coincidental event and can be classified into the following categories:

1. Vaccine product-related reaction
2. Vaccine quality defect-related reaction
3. Immunisation error-related reaction
4. Immunisation anxiety-related reaction (also known as immunisation stress-related response)
5. Coincidental event.

Ongoing post-marketing AEFI surveillance through a national spontaneous (passive) surveillance system is important in detecting AEFI that may not have been identified in pre-registration vaccine trials.

Anyone can report AEFI to the TGA, with the main categories of reporters being state and territory health departments, health professionals, vaccine companies, and consumers (members of the public).² All reported AEFI are entered into the Australian Adverse Event Management System (AEMS) database. Where the initial report contains insufficient information, the TGA may contact the reporter or relevant state or territory health department to elicit further information. The TGA continually analyses AEFI data to detect new potential safety issues or changes to known safety issues that may require regulatory or other action. The TGA may also review select serious adverse events, using internationally consistent methods to identify whether there may be a link between a vaccine and the adverse event involved.³

Reports summarising Australian national spontaneous AEFI surveillance data have been published regularly since 2003.^{4,5} Trends in reported AEFI are influenced by many factors, including changes to the National Immunisation Program (NIP), vaccine introduction and availability, media coverage, awareness campaigns, and efforts to facilitate reporting, such as safety alerts on the TGA website and social media channels, as well as programs targeted at increasing health professional reporting. Changes to the NIP since 2005 are summarised in Table S1, and their impacts on reported AEFI trends are described in previous annual AEFI reports.

There were no changes to the NIP in 2022 to highlight. However, in response to the Japanese encephalitis outbreak across mainland Australia, various states and territories rolled out targeted Japanese encephalitis vaccination programs.^{6,7} Additionally, the mpox outbreak resulted in the MVA-BN smallpox/mpox vaccine being made available in Australia through Section 18A of the Therapeutic Goods Act 1989, a special emergency pathway that ensures a vaccine is urgently available to deal with critical threats to public health.^{7,8} Despite components of usual pharmacovigilance processes being unavailable through the Section 18A access pathway, such as specific legislated requirements of pharmaceutical sponsors, spontaneous AEFI reporting to the TGA was encouraged for the MVA-BN vaccine and reports were entered into the AEMS database.

This report summarises national spontaneous (passive) surveillance data for non-COVID-19 vaccine AEFI reported to the TGA. The report focuses on AEFI reported for vaccines administered in 2022.

Methods

AEFI data

De-identified data on all AEFI for vaccines administered up to 28 February 2023 reported to the TGA and stored in the AEMS database were extracted and provided to the National Centre for Immunisation Research and Surveillance (NCIRS) on 12 October 2023. Please refer to previous reports for a detailed description of the surveillance system.^{4,9}

AEFI report data management

Only accepted AEFI reports were included in this analysis, meaning that the report must contain sufficient information pertaining to four key elements: a reporter; a patient; one or more suspected vaccines; and one or more reaction terms.¹⁰ Reports accepted by the TGA are assigned a default decision type of “causality possible” due to the event being reported to occur after the vaccine was given.

AEFI reports were defined by unique identifiers assigned by the TGA. In this analysis, each AEFI report was assigned a date based on:

1. the earliest vaccination date associated with the report; or where a vaccination date was missing:
2. the earliest symptom onset date was used; or where dates for both vaccination and symptom onset were missing:
3. the received date (the date when the reporter of the case first received the minimum valid information as described above from the primary source) was used.

Reports with a 2022 date of vaccination, symptom onset or received date, based on the hierarchy above, were included in the 2022-specific sections of this analysis.

Where the date of birth was available, it was used to calculate age at time of vaccination, symptom onset, or received date; where date of birth was missing, the age at symptom onset provided to the TGA by the reporter was used. Reports were grouped by age into <7 years, 7-17 years, 18-64 years, and ≥65 years, in alignment with reports from previous years.

Vaccine data

Vaccines were identified by trade name (standardised term in the TGA reference dataset), and where the trade name was not specified, the generic name (active ingredients associated with a trade name) and reported product name (product name used by the reporter). Individual vaccines were grouped by antigen (or combination of antigens) and, for seasonal influenza and specific other vaccines, by type (for influenza, standard-formulation vs high-dose or adjuvanted; for Japanese encephalitis and zoster, live vs recombinant or inactivated). More than one vaccine with a “suspect” role can be included in a report, without implying that all vaccines were necessarily co-administered on the same occasion. Reports that included both non-COVID-19 and COVID-19 vaccines as “suspect” were included in the companion COVID-19 vaccine AEFI report and were excluded from this analysis.¹¹

Adverse event data

AEFI reports included reaction terms that were symptoms, signs, and/or diagnoses and were coded by TGA staff from the reporter's description into lower level terms (LLT), which were then mapped to associated preferred terms (PT) using the Medical Dictionary for Regulatory Activities (MedDRA®).^{10,12}

Standardised MedDRA queries (SMQ) are sets of MedDRA terms that have been grouped after extensive testing, analysis, and expert discussion to facilitate pharmacovigilance investigation.¹³ For this analysis, the MedDRA Browser SMQ Analysis tool, running MedDRA version 26.1, was used to group related PT to SMQ to reduce the number of unique PT under analysis while providing meaningful results.¹⁴ A narrow search was performed to increase the specificity of the PT to SMQ mapping. As individual PT may map to zero, one, or more than one SMQ, the term selected (PT or SMQ) was determined as described in Table S2. Following the decision process, a one-to-one PT-SMQ mapping was performed to ensure that each PT was counted only once and there was no overlap between different SMQ in the terms that were included.

Serious and non-serious AEFI

AEFI reports were coded as “serious” or “non-serious” based on criteria used by the World Health Organization (WHO), where an adverse event report is defined as “serious” if it involves one or more of the following outcomes:

- fatal or life-threatening condition(s);
- new or prolonged hospitalisation;
- persistent or significant disability;
- congenital anomaly or birth defect; and
- any medical event that requires an intervention to prevent the above outcomes.³

For AEFI reports submitted by sponsors (pharmaceutical companies), the seriousness classification was applied by sponsors to ensure they meet legislated requirements. For other AEFI reports submitted to the TGA, the seriousness classification either reflected the view of the reporter or may have been applied by the TGA following review.

All AEFI reports where a fatal outcome is reported, or the individual was admitted to an intensive care unit (ICU; including paediatric intensive care), are reviewed by the TGA. This review is designed to assess whether the medical condition(s) that caused the ICU admission and/or death is causally related to the vaccine and whether it represents an emerging safety concern. The TGA reviews each of these reports and considers the strength of the evidence for a link between vaccination and the condition that caused the death using a standardised process based on the World Health Organization (WHO) causality assessment guidelines.¹⁵ When the cause for the events that resulted in ICU admission and/or death is not medically obvious, not stated, or cannot be determined from the initial report, the TGA may request further information from the reporter, which may include the results of investigations relating to the ICU admission and/or death, past medical history, post-mortem examination findings, the death certificate, and/or results of a Coronial Office investigation.

Data analysis

Average annual population-based AEFI reporting rates were calculated for each state and territory and by age group using June 2022 population estimates obtained from the Australian Bureau of Statistics (ABS).¹⁶ Comparisons with previous years were made using ABS mid-year estimated resident population (ERP) data for each year from 2000 to 2021.

AEFI reporting rates per 100,000 administered doses were estimated for the year 2022. The number of doses administered for each vaccine in 2022 was obtained on 2 April 2023 from the Australian Immunisation Register (AIR), a national population-based register.¹⁷ Vaccination providers were required by law to enter into the AIR every dose of NIP and influenza vaccines administered, as well as Japanese encephalitis vaccines from 21 December 2022, and were strongly encouraged to provide information on other vaccines given.¹⁸ Vaccine doses could also be entered into the AIR retrospectively, including those administered overseas.¹⁹

All data cleaning and analyses were performed using R version 4.3.1.²⁰ Confidence intervals presented are 95% exact binomial confidence intervals for proportions. AEFI reports following COVID-19 vaccination are analysed and presented in a separate report.

Notes on interpretation

The data reported here are provisional, particularly for the fourth quarter of 2022 due to reporting delays and the late onset of some reported AEFI. In addition, AEFI may have been reported in 2022 for vaccines administered in previous years. Therefore, statistics published in this report relating to AEFI reports from years prior to 2022 may not match those in previous reports.

As this report analysed data from the AEMS database, the numbers published in this report may be different to the numbers found the Database of Adverse Event Notifications (DAEN) – medicines, a public online database maintained by the TGA that contains reports of adverse events for medicines and vaccines.²¹ Differences in case numbers between the DAEN – medicines and AEMS can be due to rejected reports, for example those with insufficient information, which remain in the Adverse Event Management System (AEMS) and are updated and added to the DAEN – medicines as and when sufficient information is provided.²² There is also a 14-day time lag between cases being entered in AEMS and then added to the DAEN – medicines. As the data for this analysis were extracted from AEMS in October 2023, there may be discrepancies with the DAEN – medicines, which would reflect any new information made available to the TGA after October 2023.

Results

In the AEMS database, there were 3,642 non-COVID-19 vaccine AEFI reports where the date of vaccination (or onset of adverse event or report received date, if the date of vaccination was not reported) was between 1 January and 31 December 2022.

Of the 3,245 reports (89.1% of total) with information on sex provided, 1,675 (51.6%) were for females and 1,570 (48.4%) were for males. Of the 1,920 reports (52.7% of total) with Indigenous status provided, 125 AEFI reports (6.5%) were for people who identified as Aboriginal and/or Torres Strait Islander. Of the 3,155 reports (86.6% of total) with age or date of birth provided, 1,491 (47.3%) were for children aged <7 years and 1,664 (52.7%) were for people aged ≥7 years.

Most AEFI reports (2,629, 72.2%) were sent by a state or territory health department (termed “regional pharmacovigilance centre” in AEMS; Figure S1), and 9.5% (345) reports were direct submissions by health professionals or other organisation (including regulatory authorities) to the TGA. Consumers submitted 5.4% (195) of AEFI reports, and 13.0% (473) of reports were sent by pharmaceutical companies. The proportion of pharmaceutical company reports increased from 2021, when this group accounted for 1.9% of all non-COVID-19 AEFI reports. However, the pharmaceutical company AEFI reporting rate of 1.8 per 100,000 total population was still within the range observed over the previous decade. Most (366; 77.4%) of the pharmaceutical company reports in 2022 were from one company relaying consumer comments pertaining to experiences of AEFI from social media sites, with all reports classified as serious by the sender. Pharmaceutical companies were the only reporter type submitting AEFI reports where the source was cited to be social media. Please note that it is possible for one case to be the subject of more than one AEFI report, where the reports have been submitted independently by multiple sources and there is insufficient information provided to confirm duplication.

Excluded from this analysis were 121 AEFI reports where non-COVID-19 vaccines were listed together with COVID-19 vaccines, which are included in the companion 2022 COVID-19 vaccine AEFI report.¹¹

Reporting rates

Dose-based reporting rates

The overall non-COVID-19 vaccine AEFI reporting rate for 2022 was 18.8 [95% CI 18.2–19.5] per 100,000 doses of non-COVID-19 vaccines administered and recorded in the AIR (Table 1).

Population-based reporting rates

The overall AEFI reporting rate for 2022 was 14.0 [95% CI 13.6–14.5] per 100,000 total population, compared with 13.4 per 100,000 in 2021 and 14.9 per 100,000 in 2020 (Table 2 and Figure 1). By comparison, the highest annual reporting rate between 2000–2021 was observed in 2010 (17.4 per 100,000 total population).

The highest age group-specific population-based AEFI reporting rate was observed in children aged <7 years (69.5 reports per 100,000 population <7 years; Table 2 and Figure 6). Compared with 2021, reporting rates of AEFI decreased in the <7 years and ≥65 years age groups. While reporting rates increased slightly in the 7–17 years and 18–64 years age groups from 2021, they were still below 2020 rates.

By jurisdiction, the highest population-based AEFI reporting rates in 2022 were in Victoria (19.9 reports per 100,000 population), Western Australia (18.4 per 100,000 population) and Tasmania (18.2 per 100,000 population). The lowest reporting rates were in Queensland (4.2 reports per 100,000 population), South Australia (7.3 per 100,000 population), and New South Wales (9.8 per 100,000 population; Table 2).

Vaccines

The non-COVID-19 vaccine most frequently listed in 2022 AEFI reports was the standard-formulation seasonal influenza vaccine (786 reports; 21.6% of total 2022 reports), followed by 13vPCV (454 reports; 12.5%), DTPa-IPV-HepB-Hib (373 reports; 10.2%), DTPa-IPV (311 reports; 8.5%) and MVA-BN (280 reports; 7.7%) (Table 3). Of the 786 AEFI reports following standard-formulation seasonal influenza vaccination, 74 (9.4%) were classified as serious and 250 (31.8%) were reported in children aged <7 years (Table 3).

For each respective age group, the vaccines with the highest number of AEFI reports in 2022 were 13vPCV (in children aged <7 years), HPV vaccine (in children and adolescents aged 7-17 years), standard-formulation seasonal influenza vaccine (in people aged 18-64 years), and high-dose or adjuvanted seasonal influenza vaccine (in people aged ≥65 years) (Table 1). These trends remained the same as 2021 (Figures 3-6).⁵

Reflecting vaccination activities in response to significant public health events in 2022, there was a corresponding increase in AEFI reporting for Japanese encephalitis vaccines (23 reports in total across vaccine brands in 2022, compared to 1 report in 2021), and AEFI reports for the MVA-BN smallpox/mpox vaccine were recorded in AEMS for the first time (280 reports).

Adverse events

The most frequently reported PT or SMQ in 2022 was hypersensitivity (691 reports; 19.0%; Table 4), with 8.5% classified as serious. Most reports of hypersensitivity were in children aged <7 years (398 reports, 57.6% reports of hypersensitivity), most commonly following 13vPCV (85 reports, 21.3% reports of hypersensitivity in the <7 years age group).

In order of frequency, the next most frequently reported adverse events were the MedDRA PT/SMQ “medication errors” (678 reports; 18.6%; further detail of terms included in Table S3), injection site reaction (567 reports; 15.6%), pyrexia (512 reports; 14.1%), and the MedDRA SMQ grouping of “gastrointestinal non-specific symptoms and therapeutic procedures” (490 reports; 13.5%; Table S3 provides further details regarding terms included).

In the context of AEFI, the term “medication errors” denotes vaccination errors, and in the ≥7 age group, this was the most frequently reported PT / SMQ (310 reports). Notably, in 534 (78.9%) reports of “medication errors”, there were no adverse events reported in association with the error, noting that it is possible after the error has been reported for an associated adverse event to occur (and not be captured in the error report). Six AEFI reports involving “medication errors” were classified as serious, and in 153 (22.6%) reports of “medication errors”, more than one vaccine was reported. Compared to 2021, there was an increase in reports of vaccination errors, across all age groups and vaccines (from 380 reports, representing 11.3% of all 2021 AEFI reports, to 678 [18.6% of reports] in 2022). There was an increase in the reporting of errors both from health professionals directly to the TGA (from 17 reports of errors in 2021 to 88 reports in 2022) and to the TGA from

state/territory health departments (from 353 reports in 2021 to 578 reports in 2022). The vaccine most frequently implicated in a report of “medication errors” was the standard formulation seasonal influenza vaccine, with 129 reports (19.0% of reports with “medication errors” included), followed by the high dose or adjuvanted influenza vaccine, with 78 reports (11.5%).

Serious adverse events

Most AEFI reports in 2022 (2,983 reports; 81.9%) were coded as non-serious (Figure 1). However, the remaining 659 (18.1%) AEFI reports classified as serious represented an increase compared to 2021, where 6.5% of all AEFI reports received a serious designation.⁵

Vaccines with the highest counts of serious reports were unspecified zoster (278 serious reports; 99.6% for vaccine; Table 3), standard-formulation seasonal influenza (74, 9.4%), rotavirus (67, 16.5%), varicella (58, 71.6%) and 13vPCV (50, 11.0%; Table 3). Of note, all 278 reports of serious adverse events following an unspecified zoster vaccine were reported by a pharmaceutical company, with the accompanying free text case narrative nominating a social media page as the source of information. This was also the case for 54 of the 58 serious adverse events following varicella vaccine.

The PT/SMQ associated with the highest count of serious adverse events was “lack of efficacy / effect” (370 serious reports, 98.7% of reports for this PT/SMQ; Table 4). Notably, 341 of these reports also contained the term “herpes zoster”, and were submitted by the same pharmaceutical company as above, with the source of information attributed to social media.

When all reports with a social media source were excluded, the remaining 293 serious AEFI reports represented 8.0% of all AEFI reported in 2022, which was more closely aligned with the 2021 findings. The standard-formulation seasonal influenza vaccine then became the vaccine associated with the highest count of serious adverse event reports (73 reports). With the exclusion of reports originating from social media, the PT/SMQ associated with the highest count of serious adverse events was the MedDRA SMQ grouping of “gastrointestinal non-specific symptoms and therapeutic procedures” (54 serious reports, 11.0% of reports for this PT/SMQ) followed by pyrexia (49 serious reports, 9.6% for PT/SMQ), reflecting both the total number of AEFI reported (both serious and non-serious) for each PT/SMQ in 2022, and the trends observed in 2021.

Thirteen adverse events with a fatal outcome were reported to the TGA following a non-COVID vaccine in 2022. The reports involved a range of combinations of child and adult vaccines. Five deaths occurred in infants (all aged less than 12 months), 5 deaths occurred in adults (age range 55 to 78 years, median age 74 years), and 3 deaths occurred in individuals whose age and date of birth were not known. None of the 13 deaths were determined, following detailed TGA review, to be causally related to the vaccine(s) received.

Of the 5 reports in infants, 3 were referred to the coroner who did not identify a link to vaccination. The fourth case was reported as having occurred in the 1980s, with insufficient information available for further assessment by the TGA. The final case was submitted by a pharmaceutical sponsor, with the cited source being a case report published in the academic literature, and occurred in a child with medical comorbidities that were already listed within the “Special warnings and precautions for use” section of the product information (PI) for the vaccine that was nominated in the adverse event report.

Of the 5 reports in adults, 2 described deaths from conditions not associated with the vaccine(s) administered, two described deaths from conditions with other possible causes for the event, and one contained insufficient information to fully assess the case and determine an association with the vaccine.

All 3 of the reports involving individuals without a documented age or date of birth were identified from a social media service and contained insufficient information to fully assess the case and determine an association with the vaccine.

Reporting of a death to the TGA does not mean that the vaccine caused the death, or that the individual completing the report considers that the death was caused by a vaccine. The TGA strongly encourages consumers and health professionals to report suspected adverse events, particularly serious or fatal events, regardless of the likelihood that the vaccine was the cause of an individuals' death. The TGA reviews all AEFI reports where a fatal outcome is reported (additional details in Methods section).

All reports, including fatal reports, are de-identified and published in the Database of Adverse Event Notification (DAEN) – medicines.²¹ Publication of a report in the DAEN – medicines does not mean that the vaccine caused the adverse event. All reports of death are also included in the TGA safety monitoring data, even if a coroner or expert panel has concluded that the death is unrelated to vaccination.

Discussion

In 2022, the annual AEFI reporting rate for non-COVID-19 vaccines was 14.0 per 100,000 population. This population-based rate represented a slight increase from 2021, but remained below the rates observed in the years immediately preceding the COVID-19 pandemic.

As was the case in previous years, the highest AEFI reporting rate per 100,000 population was observed in children <7 years of age, reflecting the fact that more doses of vaccines are typically administered to each individual in this age group.

The vaccines with the highest counts of AEFI reports in each age group remained the same in 2022, as compared with 2021. However, the reporting rates per 100,000 doses were lower for most vaccines. This may be related to more doses of vaccines being administered in the ≥7 years age groups. Additionally, there were larger than usual numbers of reports where the vaccine was not clearly identified (such as unspecified zoster, pneumococcal and tetanus-containing vaccines), which do not correspond to specific dose count denominators from the AIR to allow calculation of reliable reporting rates per 100,000 doses.

Many of the reports of unspecified vaccines arose from pharmaceutical sponsors, where sources such as consumer self-reports on social media channels monitored by the sponsor may have led to onward AEFI reporting to the TGA. All reports sourced in this manner in 2022 were classified as serious, however, this was based on limited information which was generally unable to be further verified. Reporting from social media sources resulted in an inflation of serious adverse events for specific vaccines and MedDRA terms. While pharmaceutical companies are required to report any AEFI detected through their surveillance mechanisms, including social media channels, to the TGA, reports from social media sources tend to be of lower quality as they often contain limited information, and it is not possible to identify and contact either the patient or a treating clinician to obtain missing information.

The events of 2022 also included two outbreaks of vaccine-preventable diseases (VPDs) that had not previously had significant circulation in Australia: mpox and Japanese encephalitis. Vaccination was used as a prevention and control strategy for both outbreaks, resulting in the introduction of the MVA-BN vaccine to Australia, and an increased use of existing Japanese encephalitis vaccines. The rollout of MVA-BN vaccination programs was reflected in the adverse event reporting observed in the age groups where most vaccine doses were administered. The most frequently reported adverse events for the MVA-BN vaccine were injection site reaction, headache, chest pain, dyspnoea, and nonspecific gastrointestinal symptoms. Of these, injection site reaction, headache, and nonspecific gastrointestinal symptoms were identified as very common in clinical trial data and included in the PI for MVA-BN.²³ Chest pain and dyspnoea were not listed in the PI as pre-licensure adverse events. A review of global post-marketing data undertaken by the pharmaceutical sponsor showed that with more than 1.7 million doses of vaccine administered worldwide, the frequencies of acute myocardial infarction, myocarditis, and pericarditis were each lower than 1 event per 100,000 doses, which was consistent with rates observed in clinical trials.²⁴

While there was a slight increase in the number of AEFI reports for the live and inactivated Japanese encephalitis vaccines compared to previous years, there were insufficient reports for either vaccine for useful analysis of the frequencies of each reported adverse event. Additionally in 2022, there was an expansion in jurisdictional eligibility for funded influenza vaccines.^{7,25} This

change was reflected in corresponding increases both in the number of influenza vaccine doses administered, and in AEFI reports following influenza vaccines, resulting in similar or lower AEFI reporting rates per 100,000 doses administered in each age group (Table 1).

Hypersensitivity was the most frequently reported non-COVID-19 AEFI in 2022 (19.0% of all AEFI reports), moving from being second most frequent in 2021. Notably, medication (vaccination) errors were in second place, featuring in 18.6% of all non-COVID-19 AEFI reports, and relatively evenly spread across the <7 years and ≥7 years age groups. Most vaccine error reports were not associated with reports of accompanying adverse events, potentially indicating that most errors did not result in adverse outcomes at the time of reporting the vaccination error (but does not preclude AEFI developing subsequently; it is possible to update a previously submitted report with emerging developments, and health professionals are encouraged to do so). State and territory health departments investigate and address vaccination error reports where necessary.

The increase in both the number and proportion of vaccination error reports may represent an increased general awareness among health professionals to be alert to vaccination errors, and to report errors to the TGA either directly or indirectly via jurisdictional health departments. Additionally, during the COVID-19 vaccination rollout, the TGA conducted awareness campaigns (including the use of several social media channels) targeting health professionals and the public, with the aim of reminding and encouraging reporting of all AEFI, which may have also indirectly contributed to an increase in AEFI reporting for non-COVID vaccines.^{26,27} While the vaccines associated with the most vaccination error reports were the standard formulation and the high dose or adjuvanted formulation influenza vaccines, this finding likely represented that in 2022, these two groups of vaccines were the most frequently and second most frequently administered vaccines respectively (excluding COVID-19 vaccines; Table 1). Potential additional challenges with the influenza vaccine were that the lower registered age for the Influvac Tetra and Flucelvax Quad vaccines were extended in 2022, and the Fluzone high dose quadrivalent influenza vaccine formulation was introduced as a privately available vaccine for older adults.²⁸ However, the latter vaccine was not implicated in any reports of vaccination error.

Safety data for influenza and NIP vaccines were also collected throughout 2022 by AusVaxSafety, the national active participant-based surveillance system for AEFI using digital survey methods.²⁹ AusVaxSafety surveillance also commenced during 2022 for the MVA-BN vaccine, coinciding with its initial availability in Australia.³⁰ The differences in TGA and AusVaxSafety methodology preclude direct comparison of findings between the two systems. However, AusVaxSafety data has generally corroborated TGA spontaneous surveillance findings throughout this period, and reported a high level of safety for these vaccines, consistent with known profiles.

As is the case with any spontaneous surveillance system, vaccine safety monitoring by the TGA relies on adverse events being reported. Therefore, a limitation to this analysis is underreporting, which also means that AEFI reporting rates cannot be used as proxy for AEFI incidence rates.^{10,31} Reporting rates may also be affected by external factors, such as media or social media attention. AEFI reports may vary significantly in completeness and quality of information, and are not always verified against verifiable clinical data. Each AEFI report can include multiple vaccines, vaccination dates, AEFI, and AEFI onset dates. Therefore, it is not always possible to associate specific vaccines to specific AEFI and AEFI onset dates. Seriousness criteria may be applied inconsistently by different reporters, and is therefore not necessarily a reliable guide to the safety profile of a vaccine. Additionally, the analytical decision to include 121 adverse event reports where both COVID-19 and non-COVID-19 vaccines were nominated in the companion COVID-19 vaccines

report, and not this report for all other vaccines, would have led to a decrease, albeit nominal, in AEFI reporting rates for specific vaccines in this report.¹¹

In addition, vaccination data from the AIR, used to calculate AEFI rates per 100,000 vaccine doses, may not be comprehensive, in that the legal requirement for vaccination providers to report vaccines administered was only applicable to NIP, influenza, and COVID-19, vaccines throughout 2022, and to JE vaccines from 21 December 2022.^{18,32} The AIR is also limited in its capture of demographic and clinical detail, meaning that it may not be possible to calculate dose-based AEFI reporting rates for specific subgroups.

Finally, it is essential to reiterate that the AEFI reported here are not necessarily causally related to vaccination, as only a temporal, not casual, association is necessary for an AEFI to be reported. The TGA strongly encourages consumers and health professionals to report suspected adverse events, even if in their view, there is only a very small chance the event was caused by a vaccine.

Conclusion

Trends observed in spontaneous AEFI reporting in Australia in 2022 were similar to those in 2021. The slight increases in some overall reporting rates, and rates within particular age groups, may be due to a combination of increased pharmaceutical sponsor reporting, additional vaccines administered in response to novel outbreaks of VPDs (mpox and Japanese encephalitis), and as part of a gradual return to pre-pandemic AEFI reporting patterns. Overall, the 2022 spontaneous AEFI reports demonstrate a high level of safety of non-COVID-19 vaccines, including vaccines in the NIP schedule.

References

1. Council for International Organizations of Medical Sciences (CIOMS) c/o World Health Organization. *Definition and Application of Terms for Vaccine Pharmacovigilance: Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance*. 2012.
2. Therapeutic Goods Administration. Reporting adverse events, <https://www.tga.gov.au/resources/resource/reference-material/reporting-adverse-events> (2021, Accessed 2024).
3. World Health Organization. Global manual on surveillance of adverse events following immunization (revised). 2016.
4. Lawrence G, Menzies R, Burgess M, et al. Surveillance of adverse events following immunisation: Australia, 2000–2002. *Communicable Diseases Intelligence* 2003; 27: 307-323.
5. Glover C, Deng L, Larter C, et al. Surveillance of adverse events following immunisation in Australia annual report, 2021. *Communicable Diseases Intelligence* 2024; 48 24/06/2024. DOI: 10.33321/cdi.2024.48.1.
6. National Centre for Immunisation Research and Surveillance. Significant events in Japanese encephalitis vaccination practice in Australia, https://ncirs.org.au/sites/default/files/2024-03/Japanese%20encephalitis_History%20table.pdf (2024, Accessed 2024).
7. Australian Government Department of Health and Aged Care. *ATAGI 2023 annual statement on immunisation*. 2023.
8. Australian Government. Federal Register of Legislation - Therapeutic Goods Act 1989, <https://www.legislation.gov.au/C2004A03952/latest/versions> (2024, Accessed 2024).
9. Lawrence G, Boyd I, McIntyre P, et al. Surveillance of adverse events following immunisation: Australia 2002 to 2003. *Communicable Diseases Intelligence* 2004; 28: 324-338.
10. O'Moore M, Jones B, Hickie M, et al. National pharmacovigilance of seasonal influenza vaccines in Australia. *Medical Journal of Australia* 2024; 221: 178-181. DOI: doi.org/10.5694/mja2.52381.
11. Huang Y, O'Moore M, Larter C, et al. [PLACEHOLDER] Surveillance of adverse events following immunisation in Australia, COVID-19 vaccines, 2022. *Communicable Diseases Intelligence* 2025.
12. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). *Introductory Guide MedDRA Version 26.1*. 2023.
13. Medical Dictionary for Regulatory Agencies. Standardised MedDRA Queries, <https://www.meddra.org/standardised-meddra-queries> (2023, Accessed 2024).
14. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). *Introductory Guide for Standardised MedDRA Queries (SMQs) Version 26.1*. 2023.
15. World Health Organization. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification, 2nd ed., 2019 update. 2021.
16. Australian Bureau of Statistics. National, state and territory population, <https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/jun-2022> (2022, Accessed 2023).
17. Services Australia. Australian Immunisation Register, <https://www.servicesaustralia.gov.au/australian-immunisation-register> (2024, accessed 2024).
18. Australian Government Department of Health and Aged Care. Mandatory reporting of Japanese encephalitis virus vaccines to the Australian Immunisation Register began on 21 December 2022, <https://www.health.gov.au/news/mandatory-reporting-of-japanese-encephalitis-virus-vaccines-to-the-australian-immunisation-register-began-on-21-december-2022> (2023, Accessed 2024).
19. Hull B, Hendry A, Dey A, et al. *Annual Immunisation Coverage Report 2022*. 2023. National Centre for Immunisation Research and Surveillance.
20. R Core Team. R: A language and environment for statistical computing.: R Foundation for Statistical Computing, Vienna, Austria, 2020.
21. Therapeutic Goods Administration. Database of Adverse Event Notifications, <https://www.tga.gov.au/safety/safety/safety-monitoring-daen-database-adverse-event-notifications/database-adverse-event-notifications-daen> (2023, Accessed 2024).

22. Therapeutic Goods Administration. DAEN - medicines: Information for consumers, <https://www.tga.gov.au/resources/resource/reference-material/daen-medicines-information-consumers#what-the-tga-does-with-information-in-the-database> (2023, Accessed 2025).
23. European Medicines Agency. Imvanex, <https://www.ema.europa.eu/en/medicines/human/EPAR/imvanex> (2024, Accessed 2024).
24. Weidenthaler H, Vidojkovic S, Martin B, et al. Real-world safety data for MVA-BN: Increased frequency of syncope following intradermal administration for immunization against mpox disease. *Vaccine* 2024; 42. DOI: 10.1016/j.vaccine.2024.05.072.
25. National Centre for Immunisation Research and Surveillance. History of immunisation in Australia, <https://ncirs.org.au/health-professionals/history-immunisation-australia> (2024, Accessed 2024).
26. Therapeutic Goods Administration - TGA. Therapeutic Goods Administration - TGA's Post October 5 2021. Facebook, 2021.
27. Therapeutic Goods Administration - TGA. Therapeutic Goods Administration - TGA's Post March 1 2022. Facebook, 2022.
28. Australian Government Department of Health. Australian Technical Advisory Group on Immunisation (ATAGI) Clinical Advice - Statement on the administration of seasonal influenza vaccines in 2022, <https://www.health.gov.au/sites/default/files/documents/2022/02/atagi-advice-on-seasonal-influenza-vaccines-in-2022.pdf> (2022, Accessed 2024).
29. Australian Government Department of Health and Aged Care. *Vaccine safety in Australia AusVaxSafety – Summary report 2022*. 2024.
30. Deng L, Lopez L, Glover C, et al. Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox. *JAMA* 2023; 329: 2091-2094. DOI: doi:10.1001/jama.2023.7683.
31. Shimabukuro T, Nguyen M, Martin D, et al. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). *Vaccine* 2015; 33: 4398-4405. DOI: doi.org/10.1016/j.vaccine.2015.07.035.
32. Tuckerman J, Blyth C, Beard F, et al. COVID-19 and changes in the National Immunisation Program: a unique opportunity to optimise the Australian Immunisation Register (AIR). *Medical Journal of Australia* 2021; 214. DOI: 10.5694/mja2.50971.

Tables

Table 1. Vaccines administered in 2022 listed as “suspect” in reports of adverse events following immunisation (AEFI) in the Adverse Event Management System database (excluding COVID-19 vaccines), by age group

Age group ^a	Vaccine ^b	AEFI reports (n) ^c	Vaccine Doses ^d	Reporting rate per 100,000 doses (95% CI)
<7 years	13vPCV	397	851,421	46.6 (42.2–51.4)
	DTPa-HepB-IPV-Hib	360	835,432	43.1 (38.8–47.8)
	DTPa-IPV	287	290,382	98.8 (87.7–111.0)
	Influenza (seasonal – standard formulation)	250	716,743	34.9 (30.7–39.5)
	Rotavirus	246	525,062	46.9 (41.2–53.1)
	DTPa	211	285,908	73.8 (64.2–84.5)
	MMR	204	304,708	66.9 (58.1–76.8)
	MMRV	204	286,478	71.2 (61.8–81.7)
	Hib	198	286,710	69.1 (59.8–79.4)
	MenB	178	302,152	58.9 (50.6–68.2)
	MenACWY	163	317,584	51.3 (43.7–59.8)
	Hepatitis B	17	83,860	20.3 (11.8–32.5)
	Hepatitis A	16	30,684	52.1 (29.8–84.7)
	23vPPV	14	9,598	145.9 (79.8–244.6)
	Tuberculosis	11	9,738	113.0 (56.4–202.0)
	Varicella	10	11,841	84.5 (40.5–155.3)
	Influenza (seasonal - high-dose or adjuvanted)	6	407	1474.2 (542.9–3181.0)
	Typhoid-hepatitis A	5	941	531.3 (172.7–1235.6)
	Typhoid	3	14,261	21.0 (4.3–61.5)
	Japanese encephalitis (live)	1	3,398	29.4 (0.7–163.9)
	Yellow fever	1	1,644	60.8 (1.5–338.4)
	All non-COVID vaccines	1,491	5,170,395	28.8 (27.4–30.3)
7-17 years	HPV	157	562,446	27.9 (23.7–32.6)
	Influenza (seasonal – standard formulation)	91	838,104	10.9 (8.7–13.3)
	dTpa	81	285,645	28.4 (22.5–35.2)
	MenACWY	54	244,114	22.1 (16.6–28.9)
	MenB	34	37,187	91.4 (63.3–127.7)
	Hepatitis B	8	14,807	54.0 (23.3–106.4)
	23vPPV	7	1,672	418.7 (168.5–860.7)
	Hepatitis A	7	17,158	40.8 (16.4–84.0)
	Influenza (seasonal - high-dose or adjuvanted)	4	2,836	141.0 (38.4–360.7)
	Typhoid-hepatitis A	4	4,002	100.0 (27.2–255.7)
	MMRV	3	4,276	70.2 (14.5–204.9)
	Varicella	3	9,011	33.3 (6.9–97.3)
	MMR	2	8,882	22.5 (2.7–81.3)
	Typhoid	2	21,625	9.2 (1.1–33.4)
	13vPCV	1	1,511	66.2 (1.7–368.2)
	Japanese encephalitis (live)	1	5,190	19.3 (0.5–107.3)
	DT	1	6,365	15.7 (0.4–87.5)
	All non-COVID vaccines	381	2,071,040	18.4 (16.6–20.3)
18-64 years	Influenza (seasonal – standard formulation)	373	5,813,915	6.4 (5.8–7.1)
	MVA-BN	266	44,606	596.3 (527.0–672.2)
	dTpa	65	697,722	9.3 (7.2–11.9)
	Influenza (seasonal - high-dose or adjuvanted)	40	60,812	65.8 (47–89.6)
	Zoster (RZV)	26	38,254	68.0 (44.4–99.6)
	Hepatitis B	21	211,038	10 (6.2–15.2)
	Japanese encephalitis (live)	17	46,132	36.9 (21.5–59.0)
	MMR	17	92,442	18.4 (10.7–29.4)
	23vPPV	16	12,500	128.0 (73.2–207.8)
	Varicella	10	32,539	30.7 (14.7–56.5)
	Zoster (ZVL)	11	7,460	147.5 (73.6–263.7)
	DT	9	207,700	4.3 (2–8.2)
	HPV	9	40,626	22.2 (10.1–42.0)
	13vPCV	7	28,706	24.4 (9.8–50.2)
	Typhoid-hepatitis A	6	66,830	9 (3.3–19.5)
	Hepatitis A	5	53,431	9.4 (3–21.8)
	MenB	5	14,857	33.7 (10.9–78.5)
	Hepatitis A-hepatitis B	4	39,676	10.1 (2.7–25.8)
	Typhoid	4	81,516	4.9 (1.3–12.6)
	MMRV	3	2,101	142.8 (29.5–416.7)
	Rabies	3	19,912	15.1 (3.1–44)
	dTpa-IPV	2	11,454	17.5 (2.1–63.1)
	MenACWY	2	24,615	8.1 (1–29.3)
	Japanese encephalitis (inactivated)	1	2,365	42.3 (1.1–235.4)
	All non-COVID vaccines	908	7,673,117	11.8 (11.1–12.6)
≥65 years	Influenza (seasonal - high-dose or adjuvanted)	143	3,187,272	4.5 (3.8–5.3)
	Zoster (ZVL)	76	194,245	39.1 (30.8–49)
	Zoster (RZV)	47	69,402	67.7 (49.8–90.0)
	13vPCV	43	366,319	11.7 (8.5–15.8)
	Influenza (seasonal – standard formulation)	33	269,348	12.3 (8.4–17.2)
	23vPPV	11	30,302	36.3 (18.1–64.9)
	MVA-BN	11	2,676	411.1 (205.4–734.3)
	dTpa	8	119,154	6.7 (2.9–13.2)
	Japanese encephalitis (live)	3	30,289	9.9 (2–28.9)
	Varicella	3	812	369.5 (76.3–1075.9)
	DT	2	80,957	2.5 (0.3–8.9)
	MenACWY	1	3,347	29.9 (0.8–166.4)
	Typhoid-hepatitis A	1	7,798	12.8 (0.3–71.4)
	All non-COVID vaccines	375	4,412,768	8.5 (7.7–9.4)
All ages	All non-COVID vaccines	3,642	19,327,320	18.8 (18.2–19.5)

^aAll ages^a includes AEFI reports where age was not provided.

^bAll non-COVID vaccines^b Includes AEFI reports where the vaccine was not specified and a general vaccine category (for example, “pneumococcal vaccine”) was coded as “suspect”.

^cNumber of AEFI reports in which the vaccine was coded as “suspect” with regard to causal involvement in the reported adverse event and the vaccine was administered between 1 January and 31 December 2022. More than one vaccine may be coded as “suspect” in the same report if several were administered or reported at the same time.

^dNumber of vaccine doses administered between 1 January and 31 December 2022 and recorded on the Australian Immunisation Register as at 2 April 2023

Table 2. Adverse event following immunisation reports in the Adverse Event Management System database for vaccines administered in 2022 (excluding COVID-19 vaccines), by jurisdiction

Jurisdiction ^a	AEFI reports n (%)	Annual reporting rate per 100,000 population ^b			
		Overall (95% CI) ^c	Aged <7 years ^d	Aged ≥7 years ^d	Serious AEFI ^e
ACT	71 (1.9)	15.5 (12.1–19.6)	65.5	10.8	2.2
NSW	802 (22.0)	9.8 (9.2–10.5)	39.0	6.6	1.7
NT	43 (1.2)	17.2 (12.4–23.1)	44.7	14.2	0.8
QLD	225 (6.2)	4.2 (3.7–4.8)	26.0	2.2	0.4
SA	132 (3.6)	7.3 (6.1–8.6)	44.5	4.0	0.3
TAS	104 (2.9)	18.2 (14.9–22.0)	69.2	13.6	0.2
VIC	1319 (36.2)	19.9 (18.9–21.0)	139.9	8.4	0.8
WA	513 (14.1)	18.4 (16.9–20.1)	89.7	11.2	0.5
Unknown	433 (11.9)	-	-	-	-
Australia	3642 (100)	14.0 (13.6–14.5)	69.5	7.0	2.5

a ACT: Australian Capital Territory; NSW: New South Wales; NT: Northern Territory; Qld: Queensland; SA: South Australia; Tas.: Tasmania; Vic: Victoria; WA: Western Australia.

b Average annual rates per 100,000 population calculated using June 2022 jurisdiction and total ERP estimates from the Australian Bureau of Statistics.

c 95% CI: 95% confidence interval.

d Includes only AEFI reports where an age or date of birth was reported.

e An adverse event report is defined as “serious” if it involves one or more of the following outcomes: (1) fatal or life-threatening condition(s); (2) new or prolonged hospitalisation; (3) persistent or significant disability; (4) congenital anomaly or birth defect; and (5) any medical event that requires an intervention to prevent the above outcomes. For AEFI reports submitted by sponsors (vaccine companies), the seriousness classification is applied by sponsors to ensure they meet legislated requirements. For other AEFI reports submitted to the TGA, the seriousness classification either reflects the view of the reporter or may have been applied by the TGA following review.

Table 3. Vaccines administered in 2022 listed as “suspect” in reports of adverse events following immunisation in the Adverse Event Management System (AEMS) database (excluding COVID-19 vaccines)

Vaccine ^a	AEFI reports n (%) ^b	Reports with a single suspected vaccine n (%) ^c	Serious AEFI n (%) ^d	Aged <7 years n (%) ^e	Aged ≥7 years n (%) ^e
Influenza (seasonal – standard formulation)	786 (21.6)	656 (83.5)	74 (9.4)	250 (31.8)	497 (63.2)
13vPCV	454 (12.5)	43 (9.5)	50 (11.0)	397 (87.4)	51 (11.2)
DTPa-HepB-IPV-Hib	373 (10.2)	91 (24.4)	39 (10.5)	360 (96.5)	2 (0.5)
DTPa-IPV	310 (8.5)	269 (86.8)	13 (4.2)	287 (92.6)	14 (4.5)
MVA-BN	282 (7.7)	262 (92.9)	4 (1.4)	0 (0)	279 (98.9)
Rotavirus	279 (7.7)	55 (19.7)	67 (24.0)	246 (88.2)	0 (0)
Zoster (unspecified)	279 (7.7)	279 (100)	278 (99.6)	0 (0)	18 (6.5)
MMR	226 (6.2)	56 (24.8)	17 (8.5)	204 (90.3)	19 (8.4)
MenACWY	223 (6.1)	52 (23.3)	12 (5.4)	163 (73.1)	58 (26.0)
MenB	223 (6.1)	118 (52.9)	25 (11.2)	178 (79.8)	43 (19.3)
DTPa	222 (6.1)	34 (15.3)	6 (2.7)	211 (95.0)	7 (3.2)
MMRV	211 (5.8)	27 (12.8)	6 (2.8)	204 (96.7)	6 (2.8)
Hib	200 (5.5)	14 (7.0)	8 (4.0)	198 (99.0)	1 (0.5)
Influenza (seasonal - high-dose or adjuvanted)	198 (5.4)	178 (89.9)	26 (13.1)	6 (3.0)	187 (94.4)
dTpa	184 (5.1)	92 (50.0)	7 (3.8)	24 (13.0)	154 (83.7)
HPV	169 (4.6)	95 (56.2)	6 (3.6)	1 (0.6)	166 (98.2)
Zoster (ZVL)	117 (3.2)	101 (86.3)	33 (28.2)	0 (0)	89 (76.1)
Zoster (RZV)	90 (2.5)	80 (88.9)	25 (27.8)	0 (0)	73 (81.1)
Varicella	81 (2.2)	74 (91.4)	58 (71.6)	10 (12.3)	16 (19.8)
23vPPV	51 (1.4)	29 (56.9)	1 (2.0)	14 (27.5)	34 (66.7)
Hepatitis B	50 (1.4)	32 (64.0)	8 (16.0)	17 (34.0)	29 (58.0)
Hepatitis A	30 (0.8)	15 (50.0)	4 (13.3)	16 (53.3)	12 (40.0)
Japanese encephalitis (live)	22 (0.6)	20 (90.9)	1 (4.5)	1 (4.5)	21 (95.5)
Typhoid-hepatitis A	21 (0.6)	12 (57.1)	3 (14.3)	5 (23.8)	14 (66.7)
DT	15 (0.4)	11 (73.3)	3 (20.0)	0 (0)	11 (73.3)
Tuberculosis	14 (0.4)	11 (78.6)	1 (7.1)	11 (78.6)	2 (14.3)
Pneumococcal (unspecified)	9 (0.2)	1 (11.1)	6 (66.7)	1 (11.1)	2 (22.2)
Typhoid	11 (0.3)	4 (36.4)	1 (9.1)	3 (27.3)	8 (72.7)
Hepatitis A-hepatitis B	7 (0.2)	5 (71.4)	2 (28.6)	0 (0)	4 (57.1)
Polio (unspecified)	5 (0.1)	1 (20.0)	0 (0)	2 (40.0)	3 (60.0)
Q fever	5 (0.1)	4 (80.0)	0 (0)	0 (0)	5 (100)
Tetanus (unspecified)	4 (0.1)	1 (25.0)	4 (100)	0 (0)	0 (0)
DTP	3 (0.1)	2 (66.7)	0 (0)	2 (66.7)	1 (33.3)
Meningococcal (unspecified)	3 (0.1)	1 (33.3)	1 (33.3)	1 (33.3)	2 (66.7)
Pertussis	3 (0.1)	1 (33.3)	0 (0)	2 (66.7)	1 (33.3)
Rabies	3 (0.1)	1 (33.3)	2 (66.7)	0 (0)	3 (100)
dTpa-IPV	2 (0.1)	1 (50.0)	1 (50.0)	0 (0)	2 (100)
Cholera	1 (0.03)	0 (0)	0 (0)	0 (0)	1 (100)
Hib-MenCY	1 (0.03)	0 (0)	1 (100)	1 (100)	0 (0)
Japanese encephalitis (inactivated)	1 (0.03)	1 (100)	0 (0)	0 (0)	1 (100)
PCV (unspecified)	1 (0.03)	1 (100)	0 (0)	1 (100)	0 (0)
Yellow Fever	1 (0.03)	1 (100)	0 (0)	1 (100)	0 (0)
Hib-MenC	1 (0.03)	0 (0)	1 (100)	0 (0)	0 (0)

^aSee abbreviations for full vaccine names.

^bNumber of AEFI reports in which the vaccine was coded as “suspect” with regard to causal involvement in the reported adverse event and the vaccination was administered between 1 January and 31 December 2022. More than one vaccine may be coded as “suspect” if several were administered or reported at the same time.

^cAEFI reports where only one vaccine was coded as “suspect” with regard to causal involvement in a reported adverse event; note that in reports where more than one vaccine was nominated, this does not necessarily imply concomitant administration of nominated vaccines.

^dAn adverse event report is defined as “serious” if it involves one or more of the following outcomes: (1) fatal or life-threatening condition(s); (2) new or prolonged hospitalisation; (3) persistent or significant disability; (4) congenital anomaly or birth defect; and (5) any medical event that requires an intervention to prevent the above outcomes. For AEFI reports submitted by sponsors (vaccine companies), the seriousness classification is applied by sponsors to ensure they meet legislated requirements. For other AEFI reports submitted to the TGA, the seriousness classification either reflects the view of the reporter or may have been applied by the TGA following review.

^eIncludes only AEFI reports where an age or date of birth has been reported.

^fPercentages are calculated for the number of AEFI reports where the vaccine was coded as “suspect” with regard to causal involvement in the event.

Table 4. The 30 most frequently reported adverse events classified by MedDRA Preferred Terms (PTs) or Standardised MedDRA queries (SMQs), in reports of adverse events following immunisation in the Adverse Event Management System database for vaccines administered in 2022 (excluding COVID-19 vaccines)

Adverse event PT or SMQ	AEFI reports n (%) ^a	Reports with a single reported adverse event n (%) ^{be}	Serious AEFI n (%) ^{ce}	Aged <7 years n (%) ^{de}	Aged ≥7 years n (%) ^{de}
Hypersensitivity	691 (19.0)	198 (28.7)	59 (8.5)	398 (57.6)	264 (38.2)
Medication errors	678 (18.6)	534 (78.9)	6 (0.9)	334 (49.3)	310 (45.8)
Injection site reaction	567 (15.6)	220 (38.8)	8 (1.4)	254 (44.8)	302 (53.3)
Pyrexia	512 (14.1)	7 (1.4)	49 (9.6)	303 (59.2)	202 (39.5)
Gastrointestinal nonspecific symptoms and therapeutic procedures	490 (13.5)	29 (5.9)	55 (11.2)	211 (43.1)	271 (55.3)
Lack of efficacy/effect	375 (10.3)	2 (0.5)	370 (98.7)	4 (1.1)	32 (8.5)
Herpes zoster	365 (10.0)	11 (3.0)	353 (96.7)	0 (0)	38 (10.4)
Haemodynamic oedema, effusions and fluid overload	277 (7.6)	54 (19.5)	22 (7.9)	172 (62.1)	98 (35.4)
Headache	259 (7.1)	1 (0.4)	23 (8.9)	15 (5.8)	235 (90.7)
Fatigue	237 (6.5)	2 (0.8)	16 (6.8)	52 (21.9)	179 (75.5)
Myalgia	187 (5.1)	2 (1.1)	6 (3.2)	16 (8.6)	169 (90.4)
Dyspnoea	165 (4.5)	3 (1.8)	17 (10.3)	33 (20.0)	130 (78.8)
Lethargy	157 (4.3)	0 (0)	16 (10.2)	74 (47.1)	83 (52.9)
Arthralgia	142 (3.9)	1 (0.7)	11 (7.7)	5 (3.5)	134 (94.4)
Pain	131 (3.6)	2 (1.5)	90 (68.7)	8 (6.1)	48 (36.6)
Injection site erythema	112 (3.1)	9 (8.0)	6 (5.4)	74 (66.1)	36 (32.1)
Injection site pain	112 (3.1)	15 (13.4)	5 (4.5)	15 (13.4)	93 (83.0)
Cough	111 (3.0)	1 (0.9)	5 (4.5)	50 (45.0)	61 (55.0)
Convulsions	108 (3.0)	41 (38.0)	34 (31.5)	67 (62.0)	27 (25.0)
Chills	105 (2.9)	0 (0)	3 (2.9)	18 (17.1)	86 (81.9)
Chest pain	98 (2.7)	8 (8.2)	9 (9.2)	0 (0)	96 (98.0)
Oropharyngeal conditions (excl neoplasms, infections and allergies)	95 (2.6)	4 (4.2)	6 (6.3)	16 (16.8)	76 (80.0)
Angioedema	89 (2.4)	9 (10.1)	6 (6.7)	44 (49.4)	43 (48.3)
Erythema	85 (2.3)	1 (1.2)	6 (7.1)	48 (56.5)	36 (42.4)
Dizziness	83 (2.3)	2 (2.4)	10 (12.0)	1 (1.2)	78 (94.0)
Syncope	76 (2.1)	29 (38.2)	10 (13.2)	6 (7.9)	69 (90.8)
Malaise	73 (2.0)	0 (0)	8 (11.0)	7 (9.6)	65 (89.0)
Pain in extremity	73 (2.0)	4 (5.5)	4 (5.5)	15 (20.5)	55 (75.3)
Palpitations	71 (1.9)	2 (2.8)	4 (5.6)	0 (0)	70 (98.6)
Influenza like illness	67 (1.8)	13 (19.4)	5 (7.5)	16 (23.9)	44 (65.7)

^aNumber of AEFI reports in which the PT or SMQ was reported. More than one PT/SMQ may be recorded on the same report.

^bAEFI reports where only one PT or SMQ was reported.


^cAn adverse event report is defined as "serious" if it involves one or more of the following outcomes: (1) fatal or life-threatening condition(s); (2) new or prolonged hospitalisation; (3) persistent or significant disability; (4) congenital anomaly or birth defect; and (5) any medical event that requires an intervention to prevent the above outcomes. For AEFI reports submitted by sponsors (vaccine companies), the seriousness classification is applied by sponsors to ensure they meet legislated requirements. For other AEFI reports submitted to the TGA, the seriousness classification either reflects the view of the reporter or may have been applied by the TGA following review.

^dIncludes only AEFI reports where an age or date of birth has been reported.

^ePercentages are calculated for the number of AEFI reports where the PT or SMQ was reported.


Figures

Figure 1. Adverse event following immunisation reports in the Adverse Event Management System database for vaccines administered from 2000 to 2022 (excluding COVID-19 vaccines), by year



For reports where the date of vaccination was not recorded, the date of symptom onset or the received date (when the event was reported to the sender of the case) was used. For more details on changes to the National Immunisation Program, please refer to Table S1. Population data was sourced from ABS, and represents the mid-year total Australian ERP for each calendar year.

Figure 2. Reporting rates of adverse events following immunisation per 100,000 population in the Adverse Event Management System database from 2000 to 2022 (excluding COVID-19 vaccines), by year and age group



For reports where the date of vaccination was not recorded, the date of symptom onset or the received date (when the event was reported to the sender of the case) was used. For more details on changes to immunisation programs (including the National Immunisation Program), please see Table S1. Population data was sourced from ABS, and represents the mid-year total Australian ERP for each calendar year.

Figure 3a. Adverse event following immunisation reports for children aged <7 years in the Adverse Event Management System database from 2000 to 2022 (selected vaccines**), by year and vaccine – vaccines with first National Immunisation Program (NIP)-funded primary dose administered at under 6 months of age




Figure 3b. Adverse event following immunisation reports for children aged <7 years in the Adverse Event Management System database from 2000 to 2022 (selected vaccines**), by year and vaccine – vaccines with first National Immunisation Program (NIP) funded primary dose administered at or above 6 months of age




Figure 3c. Adverse event following immunisation reports for children aged <7 years in the Adverse Event Management System database from 2000 to 2022 (selected vaccines**), by year and vaccine – vaccines funded under National Immunisation Program (NIP) for specific population subgroups only






Figure 3d. Adverse event following immunisation reports for children aged <7 years in the Adverse Event Management System database from 2000 to 2022 (selected vaccines**), by year and vaccine – influenza vaccines



Notes: **Seasonal std* = standard formulation of the seasonal influenza vaccine; **Vaccines are selected for inclusion in figure 2 overall if they have been in use in the selected age group for ≥2 consecutive years, and if they are a) funded under the NIP for any population subgroup within the selected age group in 2022; b) one of the five most common vaccines associated with spontaneous AEFI reports in 2022; or c) have been implicated in a vaccine safety event of note from year 2000 onwards and/or have been implicated in a large proportion of historical spontaneous AEFI reports.

For reports where the date of vaccination was not recorded, the date of symptom onset or the received date (when the event was reported to the sender of the case) was used. For more details on changes to immunisation programs (including the National Immunisation Program), please see Table S1.


Figure 4. Adverse event following immunisation reports for people aged 7 to 17 years in the Adverse Event Management System database from 2000 to 2022 (selected vaccines only**), by year and vaccine



Notes: **"Seasonal std" = standard formulation of the seasonal influenza vaccine; **Vaccines are selected for inclusion in figure if they have been in use in the selected age group for ≥2 consecutive years, and if they are a) funded under the NIP for any population subgroup within the selected age group in 2022; b) one of the five most common vaccines associated with spontaneous AEFI reports in 2022; or c) have been implicated in a vaccine safety event of note from year 2000 onwards and/or have been implicated in a large proportion of historical spontaneous AEFI reports.

For reports where the date of vaccination was not recorded, the date of symptom onset or the received date (when the event was reported to the sender of the case) was used. For more details on changes to immunisation programs (including the National Immunisation Program), please see Table S1.


Figure 5. Adverse event following immunisation reports for people aged 18 to 64 years in the Adverse Event Management System database from 2000 to 2022 (selected vaccines only), by year and vaccine



Notes: **Seasonal std” = standard formulation of the seasonal influenza vaccine; “Seasonal hd” = high-dose or adjuvanted formulation of the seasonal influenza vaccine; **Vaccines are selected for inclusion in figure if they have been in use in the selected age group for ≥2 consecutive years, **and** if they are a) funded under the NIP for any population subgroup within the selected age group in 2022; b) one of the five most common vaccines associated with spontaneous AEFI reports in 2022; c) have been implicated in a vaccine safety event of note from year 2000 onwards and/or have been implicated in a large proportion of historical spontaneous AEFI reports; or d) provides useful information as a comparator to another vaccine included in the figure (example: RZV as a comparator to ZVL).

For reports where the date of vaccination was not recorded, the date of symptom onset or the received date (when the event was reported to the sender of the case) was used. For more details on changes to immunisation programs (including the National Immunisation Program), please see Table S1.

Figure 6. Adverse event following immunisation reports for people aged ≥65 years in the Adverse Event Management System database from 2000 to 2022 (selected vaccines only**), by year and vaccine



Notes: **“Seasonal std” = standard formulation of the seasonal influenza vaccine; “Seasonal hd” = high-dose or adjuvanted formulation of the seasonal influenza vaccine; **Vaccines are selected for inclusion in figure if they have been in use in the selected age group for ≥2 consecutive years, **and** if they are a) funded under the NIP for any population subgroup within the selected age group in 2022; b) one of the five most common vaccines associated with spontaneous AEFI reports in 2022; c) have been implicated in a vaccine safety event of note from year 2000 onwards and/or have been implicated in a large proportion of historical spontaneous AEFI reports; or d) provides useful information as a comparator to another vaccine included in the figure (example: RZV as a comparator to ZVL).

For reports where the date of vaccination was not recorded, the date of symptom onset or the received date (when the event was reported to the sender of the case) was used. For more details on changes to immunisation programs (including the National Immunisation Program), please see Table S1.

Supplementary Material

Table S2. Notable changes in national or jurisdictional immunisation policy, and in the National Immunisation Program (2005–2022), excluding COVID-19 vaccines^{18,25}

Year	Change
2022	December 2022 Mandatory reporting to AIR for all JE vaccines administered.
	August 2022 Intradermal administration of MVA-BN added to recommendations as an alternative route for pre-exposure prophylaxis.
	July 2022 First replication-deficient modified vaccinia Ankara–Bavarian Nordic, MVA-BN vaccine made available via a special emergency pathway under section 18A of the <i>Therapeutic Goods Act</i> 1989. MVA-BN recommended for both pre-exposure and post-exposure prophylaxis against mpox.
	June 2022 NSW, Qld, Vic, SA and WA governments provided state-funded influenza vaccination program for all residents from 1 June–30 June 2022.
	April 2022 The recombinant zoster vaccine is recommended for use in immunocompromised adults aged ≥ 18 years.
	March 2022 Due to changes in the epidemiology of JE in Australia, JE vaccination recommended in individuals aged ≥ 2 months in high-risk settings (as advised by jurisdictional public health authorities).
2021	July 2021 Mandatory reporting to AIR for all NIP vaccines administered.
	March 2021 Mandatory reporting to AIR for all influenza vaccines administered.
2020	July 2020 Funded schedule expanded for Aboriginal and Torres Strait Islander children living in the NT, SA, QLD and WA from 13vPCV at 2, 4, 6 and 12 months (3+1) to include an additional dose of 23vPPV at 4 years of age and a 2nd dose 5–10 years later. A single dose of 13vPCV is recommended and funded for Aboriginal and Torres Strait Islander adults at 50 years of age, followed by a dose of 23vPPV 12 months later and a 2nd dose of 23vPPV 5–10 years after that. A single dose of 13vPCV is recommended and funded for non- Aboriginal and Torres Strait Islander adults at 70 years of age, replacing the previously funded dose of 23vPPV at 65 years of age. Meningococcal B vaccine funded for all Aboriginal and Torres Strait Islander children (age <12 months) and individuals of any age with specified high risk medical conditions. Catch-up available for all Aboriginal and Torres Strait Islander children <2 years of age (up to 23 months) for 3 years - until 30 June 2023.
	March 2020 All children aged 6 months to <5 years funded for influenza vaccine under NIP. First enhanced quadrivalent influenza vaccine (adjuvanted) funded nationally for adults aged 65 years and over.
2019	December 2019

In SA, multicomponent recombinant meningococcal B vaccine catch-up for children from 12 months to <4 years of age ceased on 31 December 2019

April 2019

Meningococcal ACWY conjugate vaccine funded under the NIP for adolescents aged 14–16 years delivered through a school-based program and adolescents aged 15 to 19 years delivered through primary care providers as part of an ongoing catch-up program.

March 2019

NT: annual seasonal influenza vaccination program funded for all children aged 6 months to < 5 years.

February 2019

Annual seasonal influenza vaccination funded on the national childhood vaccination schedule for all Australian children aged 6 months – <5 years.

Aboriginal and Torres Strait Islander children and adolescents aged 5–14 years of age funded for influenza vaccine under NIP.

2018

October 2018

Multicomponent recombinant meningococcal B vaccine funded by SA for children 6 weeks to 12 months of age, with catch-up for children from 12 months to <4 years of age

July 2018

Meningococcal ACWY conjugate vaccine funded for all children at 12 months of age, replacing combined Hib and meningococcal C-containing vaccine

Hib dose moved to 18 months and given as monovalent Hib vaccine.

Schedule for routine childhood vaccination with 13vPCV changed from 2, 4 and 6 months of age to 2, 4 and 12 months of age.

April 2018

Enhanced trivalent influenza vaccines (high-dose and adjuvanted) funded nationally for all adults aged ≥65 years.

Annual seasonal influenza vaccination funded by ACT, NSW, QLD, SA, TAS and VIC for all children aged 6 months – <5 years

Meningococcal A, C, Y, W-135 conjugate vaccine funded by SA for Aboriginal and Torres Strait Islander children and adolescents aged 12 months to 19 years living in the Eyre and Far North, and Flinders and Upper North regions

February 2018

Meningococcal A, C, W, Y-135 conjugate vaccine funded by ACT for grade 10 students and persons aged 16–19 years who no longer attend school

A 2-dose schedule of 9vHPV funded for adolescents aged 12–14 years, delivered through a school-based program; 4vHPV ceased to be used in the program.

January 2018

Meningococcal A, C, Y, W-135 conjugate vaccine funded by WA for children aged 12 months to <5 years

Meningococcal ACWY school-based vaccination program funded for all NSW secondary school students in Years 10 and 11, as well as adolescents aged 15 to 19 years who have not received the vaccine at school.

2017

April 2017

Meningococcal B vaccine study commenced in South Australia for grade 10–12 students at participating schools.

January 2017

Meningococcal ACWY conjugate vaccine funded until December 2017 in Western Australia, Victoria and Tasmania for grade 10–12 students; New South Wales for grade 11–12; Queensland grade 10 students and persons aged 15–19 years who no longer attend school. The Northern Territory introduced the vaccine for at-risk people aged 1–19 years living in specified remote regions and all children aged 12 months. For more details see the

2016	<p>November 2016</p> <p>Zoster vaccine (Zostavax®) provided free for people aged 70 years under the National Immunisation Program (NIP) with a five year catch-up program for people aged 71 – 79 years.</p> <p>September 2016</p> <p>The Australian Childhood Immunisation Register expands to become the Australian Immunisation Register (AIR).</p> <p>March 2016</p> <p>Free booster dose of the diphtheria, tetanus, and acellular pertussis-containing vaccine (DTPa) at 18 months of age.</p>
2015	<p>April 2015</p> <p>New immunisation requirements for family assistance payments were announced by the federal government (the 'No Jab, No Pay' policy), to come into effect on 1 January 2016. Only parents of children (aged less than 20 years) who are 'fully immunised' or on a recognised catch-up schedule remain eligible to receive the Child Care Benefit, Child Care Rebate, and/or the Family Tax Benefit Part A end-of-year supplement.</p> <p>March 2015</p> <p>Seasonal influenza vaccine funded for Aboriginal and Torres Strait Islander children aged 6 months to less than 5 years.</p> <p>From March to June 2015, the dTpa vaccine for women during the third trimester of pregnancy was funded by New South Wales, South Australia, Western Australia, the Australian Capital Territory, Victoria and Tasmania. The Northern Territory had funded it since September 2013 and Queensland since July 2014.</p> <p>A booster dose of DTPa vaccine recommended at 18 months of age (funded in March 2016).</p>
2014	<p>December 2014</p> <p>4vHPV vaccine catch-up program for males aged 14–15 years ceased</p> <p>July 2014</p> <p>dTpa vaccine was funded by Queensland for women during the third trimester of pregnancy.</p>
2013	<p>December 2013</p> <p>Secondary school Year 7 hepatitis B vaccine catch-up program ceased, as all younger age cohorts were eligible for infant immunisation under the NIP (commenced 2000).</p> <p>September 2013</p> <p>dTpa vaccine funded by NT for women during the third trimester of pregnancy and for parents of infants aged <7 months under cocoon strategy</p> <p>July 2013</p> <p>Second dose of MMR vaccine, previously given at 4 years, was brought forward to 18 months of age and delivered as MMRV vaccine.</p> <p>Combined <i>Haemophilus influenzae</i> type b (Hib) and meningococcal serogroup C (MenC) vaccine, Menitorix®, was funded for infants aged 12 months. This combination vaccine replaced the single dose of monovalent meningococcal C conjugate vaccine (MenCCV) and booster dose of monovalent Hib vaccine previously scheduled at 12 months of age.</p> <p>February 2013</p> <p>4vHPV vaccine was extended to males aged 12–13 years, delivered through a school-based program, with a catch-up program for males aged 14–15 years in 2013 and 2014.</p>
2012	<p>October 2012</p> <p>A fourth dose of Prevenar 13®, (13vPCV, a 13-valent pneumococcal conjugate vaccine) was listed on the National Immunisation Program (NIP) for Indigenous children, aged 12-18 months, residing in Queensland, South Australia, Western Australia and the Northern Territory. This replaced the booster dose of Pneumovax23®, (23vPPV, a 23-valent</p>

	pneumococcal polysaccharide vaccine) administered between 18 and 24 months of age for Indigenous children from these jurisdictions.
2011	<p>1 October 2011 to 30 September 2012</p> <p>All children aged between 12 - 35 months who had completed a primary pneumococcal vaccination course with 7vPCV were eligible to receive a free supplementary dose of Prevenar 13®</p> <p>July 2011</p> <p>Prevenar 13® replaced Prevenar® on the NIP for children at 2, 4 and 6 months of age in all states and territories except the Northern Territory which adopted 13vPCV from 1 October 2011.</p> <p>25 March 2011</p> <p>TGA issued a recall of Batch N3336 of the 23 valent pneumococcal polysaccharide vaccine 23vPPV, Pneumovax® 23. April 2011 - health professionals were advised not to administer a second or subsequent dose of Pneumovax 23 vaccine. December 2011 - Revised recommendations regarding which patients should be re-vaccinated under the NIP were provided.</p>
2010	<p>Annual vaccination with seasonal trivalent influenza vaccine (TIV, containing 3 influenza strains: A/H1N1, A/H3N2 and B) was funded under the NIP for people aged ≥6 months with medical risk factors (previously subsidised through the Pharmaceutical Benefits Scheme) and all Indigenous people aged ≥15 years (previously all Indigenous adults ≥50 years and 15–49 years with medical risk factors).</p> <p>On 23 April 2010, the use of the 2010 seasonal TIV in children <5 years of age was suspended by Australia's Chief Medical Officer due to an increased number of reports of fever and febrile convulsions post vaccination. A subsequent investigation identified that Fluvax® and Fluvax junior® (CSL Biotherapies), but neither of the other two available brands registered for use in young children, were associated with an unacceptably high risk of febrile convulsions. The recommendation to resume the use of seasonal influenza vaccine in children aged 6 months to 5 years, using brands other than Fluvax® and Fluvax junior®, was made in August 2010.</p>
2009	<p>Late 2009</p> <p>All states and territories were using the single hexavalent DTPa-IPV-Hib-HepB (Infanrix hexa®) vaccine for all children at 2, 4 and 6 months of age, due to an international shortage of <i>Haemophilus influenzae</i> type b (Hib) (PevaxHib® [monovalent] and Comvax® [Hib-HepB]) vaccines.</p> <p>September 2009</p> <p>Pandemic H1N1 2009 influenza vaccine (Panvax®) was rolled out across Australia from 30 September 2009 for people aged ≥10 years. From December 2009, the pandemic vaccine was made available to children aged 6 months to 10 years.</p>
2008	<p>April 2008</p> <p>Western Australia commenced a seasonal influenza vaccination program for all children aged 6 months to <5 years (born after 1 April 2003).</p> <p>March 2008</p> <p>Queensland, South Australia and Victoria changed from using two combination vaccines (quadrivalent DTPa-IPV and Hib-HepB) to the single hexavalent DTPa-IPV-HepB-Hib vaccine.</p>
2007	<p>July 2007</p> <p>Universal funded immunisation against rotavirus at 2 and 4 months of age (Rotarix®) or at 2, 4 and 6 months of age (Rotateq®).</p> <p>April 2007</p> <p>Funded immunisation against human papillomavirus for all Australian girls aged 12–13 years delivered through a school-based program from April 2007, with a temporary catch-up program through schools or primary care providers for females aged 13–26 years until December 2009.</p>

2005

November 2005

Universal funded immunisation against varicella at 18 months of age with a school-based catch-up program for children at 10–13 years of age not previously vaccinated and without a history of varicella infection (no funded catch-up for children 2–10 years of age).

IPV was funded to replace OPV, in combination vaccines.

January 2005

Universal funded infant 7-valent pneumococcal conjugate vaccine (7vPCV) program replaced the previous targeted childhood program, with a catch-up program for children aged <2 years.

Universal 23-valent pneumococcal polysaccharide vaccine (23vPPV) for adults aged ≥65 years replaced previous subsidy through the Pharmaceutical Benefits Scheme.

^aIncludes immunisation-related policy and key recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI).

Table S2. Description of PT to SMQ mapping


Number of SMQ mapped	Term reported
0	PT
1	SMQ
>1	SMQ chosen by clinician, or PT if preferred SMQ could not be chosen

Table S3. PT mapped to specific SMQ^a

SMQ	PTs mapped
Gastrointestinal nonspecific symptoms and therapeutic procedures	Abdominal discomfort; Abdominal distension; Abdominal pain; Abdominal pain lower; Abdominal pain upper; Abdominal symptom; Abdominal tenderness; Abnormal faeces; Anorectal discomfort; Bowel movement irregularity; Change of bowel habit; Constipation; Defaecation disorder; Defaecation urgency; Diarrhoea; Discoloured vomit; Epigastric discomfort; Eructation; Faecal volume decreased; Faeces hard; Faeces soft; Flatulence; Frequent bowel movements; Gastrointestinal pain; Gastrointestinal sounds abnormal; Infrequent bowel movements; Nausea; Non-cardiac chest pain; Oesophageal discomfort; Oesophageal pain; Overflow diarrhoea; Vomiting
Medication errors	Accidental exposure to product; Accidental overdose; Accidental underdose; Circumstance or information capable of leading to medication error; Contraindicated product administered; Device use error; Drug monitoring procedure incorrectly performed; Expired product administered; Exposure via eye contact; Extra dose administered; Inadequate aseptic technique in use of product; Inappropriate schedule of product administration; Incomplete course of vaccination; Incorrect dosage administered; Incorrect dose administered; Incorrect dose administered by device; Incorrect product administration duration; Incorrect product dosage form administered; Incorrect product formulation administered; Incorrect route of product administration; Intercepted product storage error; Labelled drug-drug interaction medication error; Medication error; Multiple use of single-use product; Product administered at inappropriate site; Product administered to patient of inappropriate age; Product administration error; Product dispensing error; Product preparation error; Product prescribing error; Product storage error; Vaccination error; Wrong patient received product; Wrong product administered; Wrong schedule; Wrong technique in product usage process

^aTable includes only those PTs found in the AEMS database, and not all possible MedDRA PTs that map to each MedDRA SMQ; mapping hierarchy in MedDRA version 26.1 used

Figure S1. Reporting rates of adverse events following immunisation per 100,000 population in the Adverse Event Management System database from 2000 to 2022 (excluding COVID-19 vaccines), by year and reporter type



For reports where the date of vaccination was not recorded, the date of symptom onset or the received date (when the event was reported to the sender of the case) was used. For more details on changes to immunisation programs (including the National Immunisation Program), please see Table S1. Population data was sourced from ABS, and represents the mid-year total Australian ERP for each calendar year.